Search

Your search keyword '"Jimbei, P."' showing total 32 results

Search Constraints

Start Over You searched for: Author "Jimbei, P." Remove constraint Author: "Jimbei, P."
32 results on '"Jimbei, P."'

Search Results

1. Infective endocarditis in adult patients with congenital heart disease

2. HBsAg isoform dynamics during NAP‐based therapy of HBeAg‐negative chronic HBV and HBV/HDV infection

3. Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP‐Based Therapy

4. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139‐Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection

5. Intentarea procedurii de apel: deficiențe normative Initiation of the appeal proceedings: normative deficiencies

7. Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry

8. The 12th Edition of the Scientific Days of the National Institute for Infectious Diseases 'Prof. Dr. Matei Bals' and the 12th National Infectious Diseases Conference

9. FINALITATEA ȘI PERSPECTIVELE ALĂTURĂRII LA APEL

10. Characteristics, management, and outcomes of patients with left-sided infective endocarditis complicated by heart failure:a substudy of the ESC-EORP EURO-ENDO (European infective endocarditis) registry

11. Correction to: Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry (Infection, (2022), 50, 5, (1191-1202), 10.1007/s15010-022-01792-0)

12. Socio-Economic Variations Determine the Clinical Presentation, Aetiology and Outcome of Infective Endocarditis: a Prospective Cohort Study from the ESC-EORP EURO-ENDO (European Infective Endocarditis) Registry

13. The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry

16. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.

18. Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a

20. Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection

21. Update on the Safety and Efficacy of REP 2139 Monotherapy and Subsequent Combination Therapy with Pegylated Interferon Alpha-2A in Caucasian Patients with Chronic HBV/HDV Co-Infection

25. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial

28. Clinical presentation, aetiology and outcomes of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study

29. HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection.

30. Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.

31. Benefit of transaminase elevations in establishing functional cure of HBV infection during nap-based combination therapy.

32. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.

Catalog

Books, media, physical & digital resources